Welcome to the
European Biotechnology Network!

The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.

The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.

Read more about our activities here.

Latest Catch

  • Adrian Rawcliffe (CFO, Adaptimmune), Philip Campbell (Commercial Director, MEPC), Helen Tayton-Martin (COO, Adaptimmune), James Dipple (CEO, MEPC), James Noble (CEO, Adaptimmune) and Paul Pavia (Head of Development, MEPC); from left to right) © Adaptimmune

    Flagship R&D facility for Adaptimmune

    07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

    The company is one of Britain’s biotech success stories: “We started up Adaptimmune as three people on Milton Park in 2008 to research into engineered T-cell receptors to fight cancer,” says Adaptimmune CEO James Noble. Meanwhile, the company employs more than 150 staff, and it is making space for even more. The company’s expanding R&D will find a new home in a flagship facility to be built in Adaptimmune’s home Milton Park.

    According to the company, construction of the 6,200 square metre purpose-built facility is already under way. The “Enterprise Zone” facility will house around 200 R&D staff, with laboratory space and associated offices as well as meeting rooms and a café. Adaptimmune has signed a 25-year lease with the business park’s owner MEPC. “We are delighted to be working closely with MEPC on this exciting new building, which will provide best-in-class laboratories to support the expansion of our R&D team and enable continuing progress with our research programmes,” said James Noble, Chief Executive Officer of Adaptimmune.

    Adaptimmune has rapidly expanded its clinical programmes over the last few years. The Oxford-headquartered company is currently running five Phase I/II trials in multiple cancers across the US, targeting the NY-ESO-1 cancer antigen in both solid and haematological cancers. Earlier this year, Adaptimmune pulled off a €157m IPO on NASDAQ. “Adaptimmune was established at Milton Park in 2008 in a small laboratory, and we have watched this pioneering company expand into a globally recognised business,” commented James Dipple, CEO of MEPC Milton Park. “We are delighted that we are able to accommodate their growth plans by building a bespoke, state of the art new building.”

    © european-biotechnology-news.com/um

    The Latest Catch is brought to you by European Biotechnology News

Featured Events

Our Corporate Members are


All events


European Biotechnology Network AISBL

Rue de la Science 14b
1040 Brussels, Belgium

Tel: +32 27 33 72 37


Join the European Biotechnology Network!

Individual Membership for natural persons is free, while Corporate Membership, for companies, institutions and research groups start from €500 p.a.

Click here to apply for network membership!

Funding Hub Strategic Partnership

European Biopharmaceutical Enterprises